A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of Care

NCT07742527 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Belantamab SC
DRUG: Belantamab IV
DRUG: Recombinant Human Hyaluronidase PH20 (rHuPH20)
DRUG: Standard of care

Sponsor

GlaxoSmithKline